Trending NewsTrending NewsTop-Rated Dividend StocksTop-Rated DividendMost-Upgraded StocksMost-UpgradedNYSE:ABBV AbbVie (ABBV) Stock Price, News & Analysis $282.95 -2.47 (-0.87%) Closing price 03:59 PM EasternExtended Trading$283.86 +0.91 (+0.32%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About AbbVie Stock (NYSE:ABBV) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get AbbVie alerts:Sign Up Key Stats Today's Range$282.59▼$287.9350-Day Range$248.75▼$285.3252-Week Range$190.75▼$291.40Volume4.17 million shsAverage Volume4.86 million shsMarket Capitalization$499.91 billionP/E Ratio26.26Dividend Yield2.45%Price Target$277.18Consensus RatingModerate Buy Company Overview AbbVie Inc. (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world. The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta. Through its Allergan aesthetics business, AbbVie also offers Botox Cosmetic, dermal fillers and other aesthetic treatments. The company’s earlier flagship product, Humira, was used to treat several inflammatory conditions and was one of the world’s leading pharmaceutical products before biosimilar competition began. AbbVie became an independent company in 2013 after being separated from Abbott Laboratories. Its acquisition of Allergan, completed in 2020, expanded its presence in medical aesthetics, eye care and other specialty markets. AbbVie is headquartered in North Chicago, Illinois, and is led by Chief Executive Officer Robert A. Michael.AI Generated. May Contain Errors. Read More AbbVie Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks92nd Percentile Overall ScoreABBV MarketRank™: 4.612356551905 of 5 starsAbbVie scored higher than 92% of companies evaluated by MarketBeat, and ranked 65th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.4 / 5Analyst RatingModerate Buy Consensus RatingAbbVie has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 1 strong buy rating, 23 buy ratings, 6 hold ratings, and no sell ratings.Upside/DownsideThe consensus price target for AbbVie is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageAbbVie has been the subject of 20 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about AbbVie's stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth15.21% Earnings GrowthEarnings for AbbVie are expected to grow by 15.21% in the coming year, from $13.94 to $16.06 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AbbVie is 26.26, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 40.18.Price to Earnings Ratio vs. SectorThe P/E ratio of AbbVie is 26.26, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 192.04.Price to Earnings Growth RatioAbbVie has a PEG Ratio of 1.30. PEG Ratios above 1 indicate that a company could be overvalued.Read more about AbbVie's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.92% of the float of AbbVie has been sold short.Short Interest Ratio / Days to CoverAbbVie has a short interest ratio ("days to cover") of 4.14.Change versus previous monthShort interest in AbbVie has recently decreased by 16.49%, indicating that investor sentiment is improving significantly. Dividend3.3 / 5Dividend StrengthStrong Dividend YieldAbbVie pays a meaningful dividend of 2.42%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthAbbVie has been increasing its dividend for 53 years.Dividend CoverageThe dividend payout ratio of AbbVie is 195.48%. Payout ratios above 75% are not desirable because they may not be sustainable.Dividend SustainabilityBased on earnings estimates, AbbVie will have a dividend payout ratio of 43.09% next year. This indicates that AbbVie will be able to sustain or increase its dividend.Read more about AbbVie's dividend. News and Social Media4.3 / 5News Sentiment0.89 News SentimentAbbVie has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 77 news articles for AbbVie this week, compared to 9 articles on an average week.Search Interest77 people have searched for ABBV on MarketBeat in the last 30 days. This is an increase of 4% compared to the previous 30 days.MarketBeat Follows83 people have added AbbVie to their MarketBeat watchlist in the last 30 days. This is an increase of 118% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, AbbVie insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,177,500.00 in company stock.Percentage Held by Insiders0.06% of the stock of AbbVie is held by insiders.Percentage Held by Institutions70.23% of the stock of AbbVie is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AbbVie's insider trading history. Receive ABBV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AbbVie and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ABBV Stock News HeadlinesAbbVie (ABBV) Unveils Phase 2a Crohn's Data And Flags 2026 ESMO ReadoutsOctober 19 at 6:08 PM | finance.yahoo.com2 High-Flying Dividend Stocks to Buy and Hold for a DecadeOctober 19 at 6:08 PM | fool.comReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.October 19 at 1:00 AM | Base Camp Trading (Ad)AbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-α4β7 Monotherapy in Moderate to Severe Crohn's DiseaseOctober 19 at 8:07 AM | finance.yahoo.comAbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-α4β7 Monotherapy in Moderate to Severe Crohn's DiseaseOctober 19 at 4:00 AM | prnewswire.com/C O R R E C T I O N - AbbVie/October 19 at 3:00 AM | gurufocus.com3 Income Stocks Under $30 That Yield More Than the 10-Year Treasury Note (ABBV)With the 10-year Treasury yielding around 5.3%, Pfizer, Energy Transfer, and Plains All American offer stocks under $30 with dividend yields between 6% and 7%.October 3, 2026 | marketbeat.com3 Healthcare Dividend Stocks Offering More Than Just Income (ABBV)AbbVie, Johnson & Johnson and Merck offer growing dividends alongside healthcare pipeline catalysts, regulatory approvals and rising analyst price targets heading into 2027.September 30, 2026 | marketbeat.comSee More Headlines ABBV Stock Analysis - Frequently Asked Questions How have ABBV shares performed this year? AbbVie's stock was trading at $228.55 on January 1st, 2026. Since then, ABBV stock has increased by 23.8% and is now trading at $282.9490. How were AbbVie's earnings last quarter? AbbVie Inc. (NYSE:ABBV) posted its quarterly earnings data on Friday, July, 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.61 by $0.04. The business's quarterly revenue was up 10.2% on a year-over-year basis. Read the conference call transcript. Does AbbVie have any subsidiaries? AbbVie subsidiaries include these companies: Mavupharma, Allergan, Stem CentRx, Pharmacyclics Inc, ImmuVen, AbbVie AB, AbbVie AG, and more. Who are AbbVie's major shareholders? AbbVie's top institutional shareholders include Assenagon Asset Management S.A. (0.10%), Hamlin Capital Management LLC (0.04%), Ferguson Wellman Capital Management Inc. (0.04%) and Mn Services Vermogensbeheer B.V. (0.03%). Insiders that own company stock include Richard A Gonzalez, Azita Saleki-Gerhardt, Robert A Michael, Nicholas Donoghoe, Jeffrey Ryan Stewart, Timothy J Richmond, Perry C Siatis, Scott T Reents, Kevin K Buckbee and David Ryan Purdue. View institutional ownership trends. How do I buy shares of AbbVie? Shares of ABBV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AbbVie own? Based on aggregate information from My MarketBeat watchlists, some other companies that AbbVie investors own include NVIDIA (NVDA), Johnson & Johnson (JNJ), AT&T (T), Pfizer (PFE), Verizon Communications (VZ), Chevron (CVX) and ExxonMobil (XOM). Company Calendar Record date for 8/14 Dividend7/15/2026Ex-Dividend for 8/14 Dividend7/15/2026Last Earnings7/31/2026Dividend Payable8/14/2026Record date for 11/16 Dividend10/15/2026Ex-Dividend for 11/16 Dividend10/15/2026Today10/19/2026Next Earnings (Estimated)10/30/2026Dividend Payable11/16/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 ABBV's financial health is in the Green zone, according to TradeSmith. ABBV has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNYSE:ABBV CIK1551152 Webwww.abbvie.com Phone(847) 932-7900Fax302-655-5049Employees57,000Year Founded2013Price Target and Rating Average Price Target for AbbVie$277.18 High Price Target$320.00 Low Price Target$225.00 Potential Upside/Downside-2.0%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage30 Analysts Profitability EPS (Trailing Twelve Months)$3.54 Trailing P/E Ratio26.26 Forward P/E Ratio20.30 P/E Growth1.3Net Income$4.23 billion Net Margins9.80% Pretax Margin13.51% Return on Equity-422.07% Return on Assets14.34% Debt Debt-to-Equity RatioN/A Current Ratio0.81 Quick Ratio0.69 Sales & Book Value Annual Sales$61.16 billion Price / Sales8.17 Cash Flow$15.02 per share Price / Cash Flow18.84 Book Value($1.83) per share Price / Book-154.62Miscellaneous Outstanding Shares1,766,790,000Free Float1,765,733,000Market Cap$499.91 billion OptionableOptionable Beta0.24 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NYSE:ABBV) was last updated on 10/19/2026 by MarketBeat.com Staff. From Our PartnersTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...Banyan Hill Publishing | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AbbVie Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AbbVie With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
